Federal contractor · EVANSTON, IL

SNC THERAPEUTICS, INC.

SNC THERAPEUTICS, INC. received $7M in federal contract obligations in FY2026, on 2 awards. Its largest customer was Departmental Offices ($7M).

Obligations · FY2026
$7M
New awards
2
Sole-source
0.0%
Single offer
0.0%
UEI
YNQPL17KGWA6
Small businessMinority-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 7MFY2026

Top buying agencies

Obligations in FY2026.

  1. Departmental Offices$7M100%
    2 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

  1. Research & development$7M100%

Where the work was performed

  1. Cook County, IL$7M100%

Integrity signals

Shares of the year's obligations, next to the country's.

  • Low competition0.0%
    US 39% · $0
  • Sole-source awards0.0%
    US 30% · $0
  • Single-offer competitions0.0%
    US 8.7% · $0
  • Urgency justifications0.0%
    US 5.1% · $0

A signal is a reason to look closer, not evidence of wrongdoing: most sole-source awards are lawful and justified.

Largest awards

  1. ARPA-H SNC QUIET STTR PHASE II$3.5M
    Departmental Offices· Cook County, IL· Research & development· Sep 24, 2026 – Sep 24, 2026· 140D0426C0123
  2. ARPA-H SNC SHIELD STTR PHASE II$3.5M
    Departmental Offices· Cook County, IL· Research & development· Sep 24, 2026 – Sep 24, 2026· 140D0426C0122

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

SNC THERAPEUTICS, INC. received $0 in federal assistance in FY2026, on 1 actions (0 new awards), −100% vs FY2025.

Assistance · FY2026
$0
New awards
0
Actions
1
Since FY2025
$350K

Assistance by fiscal year

  1. 350KFY2025
  2. 0FY2026

Largest awards

  1. TOLEROGENIC NANOTHERAPY TO DELAY TYPE I DIABETES - ABSTRACT TYPE 1 DIABETES (T1D) IS AN ENDOCRINE DISORDER CHARACTERIZED BY THE AUTOIMMUNE…$350K
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Jul 23, 2025 – Mar 26, 2026· R41DK142265

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2025–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. ZIGGURATUM, INC.$5.9M+99% in FY2026
    CHATTANOOGA, TN · 75% of this company's obligations are in markets they both serveDepartmental Offices · Scientific research and development services
  2. MAXAR MISSION SOLUTIONS INC$7.6M−105% in FY2026
    CHANTILLY, VA · 7 entities · 83% of this company's obligations are in markets they both serveDepartmental Offices · Scientific research and development services
  3. GLOBAL SECURE SHIPPING INC$12.7M−100% in FY2026
    OLD TOWN, ME · 100% of this company's obligations are in markets they both serveDepartmental Offices · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026.